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Osteoarthritis (OA) is a chronic degenerative disease involving multiple physiopathological mechanisms. The
increased prevalence of OA after menopause and the presence of estrogen receptors in joint tissues suggest that
estrogen could help prevent development of OA. This review summarizes OA research with a focus on the effects
of estrogen and selective estrogen receptor modulators (SERMs). Preclinical studies and clinical trials of estrogen
therapy have reported inconsistent results. However, almost all studies assessing SERM treatment have obtained
more consistent and favorable effects in OA with a relatively safety and tolerability profiles. At present, some
SERMs including raloxifene and bazedoxifene have been approved for the treatment of osteoporosis. In
summary, estrogen-related agents may exert both a direct effect on subchondral bone and direct and/or
indirect effects upon the surrounding tissues, including the articular cartilage, synovium, and muscle, to name
a few. Estrogen and SERMs may be particularly favorable for postmenopausal patients with early-stage OA or
osteoporotic OA, a phenotype defined by reduced bone mineral density related to high remodeling in
subchondral bone. At present, no single drug exists that can prevent OA progression. Although
estrogen-related drugs provide insight into the continued work in the field of OA drug administration, further
research is required before SERMs can become therapeutic alternatives for OA treatment.
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Osteoarthritis (OA) is a chronic, progressive disease that
affects the entire joint organ and eventually leads to joint
organ dysfunction [1]. An OA subset of high remodeling
and/or low subchondral bone mineral density (BMD)
may benefit from management with anti-resorptive
agents to inhibit OA progression [2–5]. OA is the main
cause of disability in the older population and is a socio-
economic burden worldwide.
Observational studies indicate that the prevalence of
OA is increased immensely in postmenopausal
women [6]. Further research has identified the pres-
ence of estrogen receptors (ERs) in joint tissues [7].
Moreover, the aromatase gene involved in estrogen
secretion and ER gene mutation are associated with
OA severity of the lower limb large joint [8]. Simi-
larly, polymorphisms in the ERα gene might also be* Correspondence: zhliu130@sohu.com
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gether, evidence strongly suggests that estrogen may
be involved in the development of OA.
Selective estrogen receptor modulators (SERMs) are
synthetic nonsteroidal agents with different chemical
structures that elicit diverse estrogen agonist and antag-
onist activities within different tissues [11]. However,
SERMs have shown consistent agonist activities in joint
tissues. An ideal SERM would exert favorable tissue-
selective estrogenic agonist activities in the bone, cardio-
vascular system, brain, urogenital system, vagina, and
skin, with ER neutral or anti-estrogenic activities in the
endometrium, breast, and pelvic floor [12, 13]. Import-
antly, SERM treatment has not resulted in any long-
term estrogen treatment-related adverse events to date.
Recent studies have supported that estrogen or SERMs
may have beneficial effects on joint tissues (Table 1). In
this review, relevant English-language articles concern-
ing the effects of estrogen or SERMs in OA progression
or on joint tissues were identified using the PubMed
database. The aim of this literature review was tole is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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Reduction of articular cartilage turnover and destruction,




Regulation of bone growth and remodeling, promotion
of matrix production and mineralization,




Decrease of the proliferation of rheumatoid arthritis-like
synovial cells, decrease of proinflammatory cytokine
production, reversion of experimental arthritis
Muscle Promotion of myoblast proliferation and differentiation,
reduction of muscle cell apoptosis, reversion of muscle
atrophy and contractile dysfunction
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tients, particularly osteoporotic OA patients, may benefit
from treatment with estrogen or SERMs. The findings
highlight that, at present, no single drug can prevent OA
progression, while estrogen-related drugs analyzed to-
gether provide insight into the ongoing work on OA
administration.
Estrogen therapy: inconclusive results
Direct binding of estrogen to ERs acts on joint tissues,
protecting their biomechanical structure and function,
thus maintaining overall joint health (Table 2). However,
the exact effect of estrogen on OA remains controversial
and in some cases inconsistent, likely owing to the
methodological drawbacks or the varying OA pheno-
types as detailed in the research.
Preclinical studies
A systematic review comprising controlled studies
found estrogen to have confounding effects on articu-
lar cartilage in ovariectomized (OVX) animals [14].
Interestingly, only 11 out of 22 animal studies report
beneficial actions of estrogen on OA, suggesting that
the estrogenic effect is inconclusive, which is consist-
ent with the majority of recently published literature
[15]. In fact, intraarticular injection of estrogen was
reported to actually damage the knee articular cartil-
age in OVX rabbits [16, 17], with long-term estrogen
treatment being beneficial for articular cartilage in
other animal models [18, 19]. Early studies of estro-
gen administration may therefore overestimate the
positive effect of estrogen on articular cartilage [20].
In-vivo estrogen treatment has shown inconclusive re-
sults in OA. Gao et al. [21] found that serum-free estra-
diol levels and total serum estradiol levels were
significantly lower in postmenopausal compared with
premenopausal OA women. Afzal and Khanam [22]
found that estrogen deficiency may lead to increased
serum IL-6 in postmenopausal patients with OA, whichhas been found to promote OA progression. In a murine
model of knee OA, exogenous estrogen suppressed tibia
and patella subchondral cortical bone thinning and pre-
vented patellar cartilage damage, supporting an etio-
logical role for altered estrogen signaling in OA [23].
Similarly, in an osteopenic mouse, estrogen treatment
recovered bone mass of the subchondral bone, but
although it reduced the expression of cartilage
ADAMTS-4 and ADAMTS-5, cartilage damage was not
significantly prevented [19]. However, estrogen has been
shown to improve the histological integrity of articular
cartilage and reduced cartilage and bone turnover in a
murine OA model [18]. Furthermore, in an OA OVX rat
model, 17β-estradiol treatment significantly reduced the
density of substance P and calcitonin gene-related pep-
tide immunoreactive nerve fibers in the synovial mem-
brane, suggesting that estrogen partly regulates
intraarticular neurogenic inflammation in OA joints by
modulating the expression of neuropeptides in the
synovial membrane [24]. However, in an iodoacetate-
induced temporomandibular joint OA rat model, estro-
gen administration promoted cartilage degeneration,
subchondral bone erosion, and expression of apoptosis
genes [25]. Intraarticular injection of estrogen was also
reported to actually damage the knee articular cartilage
in rabbits OA models [16, 17].
Estrogen appears to have a potential protective effect on
chondrocytes in vitro. In rabbit articular chondrocytes,
17β-estradiol has been shown to upregulate collagen type
II expression by Sp1/3, Sox-9, and ERα [26]. In another
study, 17β-estradiol treatment prevented injury-related
cell death and glycosaminoglycan release in mature articu-
lar cartilage explants, suggesting that 17β-estradiol may be
useful for treating either cartilage-related sports injuries
or OA [27]. Kumagai et al. [28] also found that 17β-
estradiol suppressed doxorubicin-induced apoptosis by
blocking volume-sensitive Cl– current in rabbit articular
chondrocytes. In cultured chondrocytes from a rat OA
model, 17β-estradiol promoted chondrocyte proliferation
via the PI3K/Akt pathway [29].
Clinical studies
Consistent with these preclinical studies, comprehensive
analysis of a multitude of clinical studies has shown that
the effects of estrogen on hand OA or other joint OA
failed to reach clear conclusions [15, 30].
On the one hand, estrogen appears to have a potential
protective effect on OA in many clinical studies. A
cross-sectional study found that postmenopausal women
who received long-term estrogen treatment had a signifi-
cantly reduced risk of any radiographic hip OA, indicat-
ing that postmenopausal estrogen management may
ameliorate hip OA [31]. In the Women’s Health Initia-
tive study [32], women receiving conjugated equine
Table 2 Effects of estrogen on joint tissues
Drug name Type of study Effects on joint tissues Reference
Estradiol In-vivo OVX + OA rabbits Cartilage degeneration [16]
β-estradiol In-vivo OVX rabbits Loss of glycosaminoglycans and collagen [17]
17β-estradiol In-vivo OVX rats Decrease of CTX-II; prevention of cartilage lesions [20]
17β-estradiol In-vivo postmenopausal OA women Decrease of 17β-estradiol after menopause [21]
Estrogen In-vivo postmenopausal OA women Estrogen deficiency may lead to increase of serum IL-6 [22]
17β-estradiol In-vivo murine with knee OA Inhibition of tibial and patellar subchondral cortical thinning and tibial
cartilage damage
[23]
17β-estradiol In-vivo OVX + OA mice Inhibition of bone resorption; decreased ADAMTS-4 and ADAMTS-5
expression
[19]
β-estradiol In-vivo OA + OVX murine Reduction of cartilage and bone turnover [18]
β-estradiol In-vivo OVX + ACLT murine Regulation of intraarticular neurogenic inflammation [24]
17β-estradiol In-vivo OA + OVX murine Potentiation of cartilage degradation and subchondral bone erosion
and mRNA expression of Fas, FasL, caspase 3, and caspase 8
[25]
17β-estradiol In-vitro rabbit chondrocytes Upregulation of type II collagen gene [26]
17β-estradiol In-vitro cow mature joint cartilage Prevention injury-related cell death and GAG release [27]
17β-estradiol In-vitro rabbit chondrocytes Inhibition of doxorubicin-induced apoptosis [28]
17β-estradiol In-vitro rat OA chondrocytes Promotion of chondrocyte proliferation [29]
Oral estrogen CSS osteoporotic white women Reduction of risk of any hip OA [31]
HRT CSS women around menopause Inverse association of current HRT use and radiological OA of the knee [35]
Oral estrogen CSS women with OA No positive association of estrogen use with radiographic knee OA [36]
ERT CSS older women Protection moderately against worsening of radiographic knee OA,
but not statistically significant
[37]
ERT CSS women Nonsignificant protective effect for incident knee osteophytes [38]
CEE RCT community-dwelling women Lower rates of any arthroplasty [32]
Estrogen CSS women Lower subchondral bone attrition and bone marrow edema-like
abnormalities
[33]
Estrogen CSS, older women No significant correlation with knee replacement of OA [39]
HT Prospective study, women around menopause Correlation highly with the hip or knee replacement rates of OA [40]
17β-estradiol RCT postmenopausal OP women Decrease of levels of COMP [34]
OA osteoarthritis, OP osteoporosis, OVX ovariectomy, CTX-II C-terminal cross-linked telopeptide type II collagen, HRT hormone replacement therapy, ERT estrogen
replacement therapy, COMP cartilage oligomeric matrix protein, ACLT anterior cruciate ligament transaction, CEE conjugated equine estrogens, HT hormonal
therapies, CSS cross-sectional study, RCT randomized controlled trial
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particularly hip replacement rates. In a cross-sectional
study, knee MRI scans identified that women receiving
estrogen had significantly less subchondral bone attrition
and bone marrow edema-like abnormalities in the knee
compared with nontreated women [33]. Likewise, a
case–control study found that estrogen treatment sig-
nificantly reduced the serum level of cartilage oligomeric
matrix protein, a marker associated with cartilage degen-
eration, suggesting that estrogen treatment may be a
novel treatment modality to prevent OA joint degener-
ation [34].
Conversely, estrogen seems to have no protective or
even damaging effect on OA in some other clinical stud-
ies. Two of the largest observational studies, the Britain
Chingford Study and the US Framingham Osteoarthritis
Study, and subsequent follow-up of these two studiesfound that estrogen treatment did not significantly re-
duce the radiographic severity of knee OA or hand OA
[35–38]. In a recent longitudinal observational study, es-
trogen therapy had no significant correlation with OA
knee replacement [39]. Furthermore, estrogen treatment
is reported to increase the joint replacement rate of OA,
which conflicts with its suggested protective effect [15].
A prospective study showed that postmenopausal estro-
gen treatment increased the risk of hip or knee replace-
ment of OA [40].
In summary, although considerable studies have found
that estrogen may have potential protective effects on OA
joints, the exact effect of estrogen on OA remains contro-
versial. The inconclusive results of estrogen in OA may be
due to the following reasons. First, estrogen may have dif-
ferent effects on the initiation and progression of OA. In-
creasing numbers of experimental and human studies have
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the subchondral bone, with increased bone turnover and
subsequent bone loss in early stages of OA [41, 42]. These
changes are followed by reduced bone turnover and further
subchondral sclerosis in the late stages of OA [41–43].
Consequently, estrogen could decrease bone turnover and
may have potential beneficial effects for early-stage OA.
Conversely, the prevention of bone loss may result in
effects that are not beneficial or are even harmful for late-
stage OA, with some studies showing an association
between high bone density and radiographic OA
changes [36, 38]. Second, estrogen may have a benefi-
cial effect on only certain subtypes of OA. Depending
on the ratio between formation and resorption, sub-
chondral bone remodeling can culminate in either a
sclerotic or an osteoporotic phenotype. Patients with
osteoporotic OA may thus achieve clinical and struc-
tural benefit from estrogen intervention [2, 3, 5].
Finally, outcome measurements in these studies vary
widely. Although some studies have reported moderate
but nonsignificant protective effects [36–38], those de-
tecting serologic or radiographic changes have shown an
overall protective effect [31, 33–35]. Conversely, incon-
sistent results are apparent in studies using joint replace-
ment patients [32, 40]. In addition to differences in trial
design, the association between estrogen replacement
therapy and the incidence of joint replacement may be
affected by nonbiological factors. For example, women
who take estrogen replacement therapy may have easier
access to health services and, as such, may be more
likely to have a joint replacement for existing OA. Fur-
thermore, it is reported that women that have under-
gone knee replacement are in higher socioeconomic
groups and are more likely to have other operations,
such as hysterectomy [40].
Taken together, although estrogen treatment elicits a
potential protective effect on OA, the identification of
OA patient phenotypes and specific OA stages should
be considered alongside therapeutic interventions in fu-
ture studies, which may lead to clearer conclusions re-
garding estrogen therapy on OA progression.
SERM treatment: consistent evidence
SERMs are a specific type of ER-binding estrogen that
have selective effects on target tissues. Present studies
support that SERMs have a more consistent beneficial
effect on bone tissue, and therefore some have been ap-
proved for treatment of osteoporosis, such as lasofoxi-
fene and bazedoxifene in Europe and the USA [44].
Subsequent studies have found that SERMs also have a
beneficial role in other joint tissues, thus maintaining
joint health as a whole. Compared with the controversial
effects of estrogen administration on OA, SERMs have
more stable and favorable effects on OA.Preclinical studies
Basic research has shown that SERMs inhibit destruc-
tion of articular cartilage and subchondral bone,
delaying OA progression. Meanwhile, SERMs have an
anti-inflammatory effect and prevent OA-like joint de-
generation as a whole (Table 3).
Intraarticular administration of tamoxifen was shown to
reduce cartilage damage and antagonize chondrodestructive
effects of high-dose estradiol in different rabbit OA models
[45–48]. Tamoxifen played a protective effect on articular
cartilage in intact male rabbits, suggesting that its thera-
peutic effect might not only be associated with its anti-
estrogenic role [47]. Furthermore, both levormeloxifene
and cis-3,4-7-hydroxy-3-phenyl-4-(4-(2pyrrolidinoethoxy)-
phenyl)chromane suppressed OVX-induced acceleration of
bone and cartilage turnover and ameliorated destruction of
cartilage in female rats [49, 50]. Andersson et al. [51] found
recently that the anti-osteoporotic drugs lasofoxifene and
bazedoxifene ameliorated cartilage and bone lesions and
the histologic grade of synovitis, indicating that they are po-
tent inhibitors of joint inflammation and destruction of car-
tilage and bone in experimental arthritis. Similarly, Saito
et al. [52] found that bazedoxifene inhibited OVX-induced
deterioration of structural properties of vertebral cancellous
bone in monkeys and improved bone strength.
The consistent effect of SERMs in vivo indicates a pro-
tective effect on chondrocytes. Kavas et al. [53] reported
that 1 μM of raloxifene reduced expression of OA-related
genes, apoptosis, and extracellular matrix-degrading en-
zymes, and increased extracellular matrix deposition and
improved mechanical properties in rat articular chondro-
cytes with OA-like degeneration. However, these effects
were reversed with increased dose, demonstrating that low-
dose raloxifene has the potential to cease or decrease cartil-
age degeneration in OA. In cultured human chondrocytes,
when raloxifene and IL-1β were coincubated in the culture
medium, proteoglycans were significantly and dose-
dependently augmented, and matrix metalloproteinase-3
and nitric oxide (NO) levels were significantly decreased,
demonstrating that raloxifene antagonized IL-1β-induced
OA-like chondrocyte changes [54]. In another study, the
natural SERM genistein antagonized lipopolysaccharide-
induced OA-like chondrocyte changes with a significant
decrease of COX-2 protein and NO level in the supernatant
of cultured human chondrocytes, indicating that genistein
may maintain joint health through an anti-inflammatory
effect [55].
Clinical studies
SERMs appear to have protective effects on joint tissues.
SERMs regulate metabolism of articular cartilage and
subchondral bone, maintain their normal biomechanical
structure and performance, and possibly delay disease
progression of OA. In addition, SERMs may have a
Table 3 Effects of selective estrogen receptor modulators on joint tissues
Drug name Type of study Effects on joint tissues Reference
Tamoxifen In-vivo rabbit with OVX +MMX-OA Reduction of cartilage damage [48]
In-vivo rabbit with MMX-OA Reduction of cartilage damage [46]
In-vivo intact male rabbit with OA Reduction of cartilage damage [47]
In-vivo rabbit with OVX +MMX-OA Antagonism of chondrodestructive effects of high-dose estradiol
intraarticular administration
[45]
CHPPPC In-vivo Sprague–Dawley rats with OVX Inhibition of the OVX-induced acceleration of bone and cartilage
turnover, and suppression of cartilage damage
[49]
Levormeloxifene In-vivo Sprague–Dawley rats with OVX Prevention of the OVX-induced cartilage and bone changes [50]
RCT postmenopausal women Decrease of CTX-I I by approximately 50 % [50]
Lasofoxifene In-vivo DBA/1 mice with OVX + arthritis Reduction of the grade of histologic synovitis and erosions on
cartilage and bone
[51]
Bazedoxifene In-vivo DBA/1 mice with OVX + arthritis Reduction of the grade of histologic synovitis and erosions on
cartilage and bone
[51]
In-vivo cynomolgus monkeys with OVX Inhibition of OVX-induced vertebral deterioration of structural
properties
[52]
Prospective study in postmenopausal women
with type 2 diabetes
Improvement of bone resorption markers [57]
RCT in postmenopausal women with OP Lowered significantly the cumulative incidences of new vertebral
fractures and maintained total hip bone mineral density
[58]
Exploratory analysis women with increased
fracture risk
Geometry-related improvements in bone strength [59]
RCT in women with menopausal symptoms Improvement of lumbar spine and total hip BMD [60]
RCT in postmenopausal women with OP Reduction of the incidences of vertebral and nonvertebral fractures [61]
Raloxifene In-vitro rat OA-like chondrocytes Ceases or reduces the matrix degeneration in OA [53]
In-vitro human OA-like chondrocytes Augmented in proteoglycans and a significant decrease of MMP-3
and NO levels
[54]
Cross-sectional study in older women with
knee OA
Less subchondral bone attrition and bone marrow edema-like
abnormalities
[33]
RCT in postmenopausal women with back or
knee pain
Amelioration of bone and joint pain [62]
Genistein In-vitro human OA-like chondrocytes Decrease of NO and IL-1β level in supernatant [55]
OA osteoarthritis, OVX ovariectomy, OP osteoporosis, MMX-OA medial meniscectomy-induced OA, CHPPPC cis-3,4-7-hydroxy-3-phenyl-4-(4-(2-pyrrolidinoethox)
phenyl)chromane, RCT randomized controlled trial, CTX-II C-terminal cross-linked telopeptide type II collagen, BMD bone mineral density, MMP matrix
metalloproteinase, NO nitric oxide
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play protective roles on the synovium and other joint tis-
sues, maintaining joint health as a whole.
In the Health, Aging and Body Composition Study co-
hort, raloxifene significantly reduced subchondral bone
attrition, bone marrow edema-like abnormalities, and
knee pain according to Western Ontario and McMaster
Universities Arthritis Index scores when compared with
the control group [33]. A further study found that
SERMs have a positive effect on cartilage metabolism. In
this placebo-controlled trial, levormeloxifene reduced
the urinary excretion of C-terminal cross-linked telopep-
tide type II collagen (CTX-II) by approximately 50 %
and restored CTX-II levels to the premenopausal range
compared with the control group, indicating that levor-
meloxifene inhibits degeneration of articular cartilage
[50]. In another study, raloxifene not only reduced theCTX-II level, but also decreased the level of the bone re-
sorptive marker CTX-I in postmenopausal women [56].
Interestingly, when women ceased levormeloxifene treat-
ment, CTX-II levels returned to baseline level, while
CTX-I was still strongly suppressed. This suggests that
SERMs may play a short-lived role on cartilage and a
long-term role on bone [56]. In recent studies, bazedoxi-
fene not only prevented bone loss and maintained BMD
by reducing bone turnover in postmenopausal women,
but also improved the microstructure of bone. Conse-
quently, bazedoxifene enhanced bone strength and re-
duced the risk of vertebral and nonvertebral fractures in
postmenopausal women [57–61]. Remarkably, Fujita
et al. [62] reported that combined raloxifene and alfacal-
cidol treatment appeared to be more effective on bone
and joint pain than alfacalcidol alone in postmenopausal
women with either back or knee pain alone, or both,
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In summary, postmenopausal women with osteopor-
otic OA might benefit from treatment with SERMs.
The mechanisms of action of SERMs within joint tis-
sues are being gradually elucidated [53, 54, 63]. In
addition to the role of SERMs on ERs and their inter-
action with coregulator proteins to produce transcrip-
tional complexes, some clinical effects of SERMs may
involve rapid actions mediated by G protein-coupled
estrogen receptor 1 (GPER1), with subsequent activa-
tion of the PI3K/Akt and/or PKC/MAPK pathways.
Consequently, tamoxifen and raloxifene have been
identified as GPER1 agonists [53].
Estrogen-related drug mechanisms of action in OA
Recent research has confirmed that significant changes
in the subchondral bone occur during OA progression
[64]. Key changes in the subchondral bone include high
bone turnover with decreased BMD and bone biomech-
anical structural damage in the early stages of OA,
which either coincide with or precede cartilage degener-
ation [64]. Subchondral bone degeneration may be the
trigger for changes in the cartilage biomechanical and
biochemical microenvironment, thus promoting cartilage
erosion and ultimately OA progression [65]. Conse-
quently, subchondral bone is a potential therapeutic tar-
get, and drugs acting on subchondral bone represent
potential disease-modifying OA drugs [2–4]. Similarly,
the main pathological change in OA is degeneration of
the articular cartilage that promotes subchondral bone
lesions during progression of OA, particularly in late
OA stages when cartilage erosion is extensive [4, 43].
Therefore, subchondral bone and cartilage are strongly
dependent on each other during the progression of OA.
In short, OA disease-modifying drugs must be able to
act on both of these joint tissues to prevent the develop-
ment and progression of OA.
Estrogen-related drugs that act on both subchondral
bone and cartilage are good candidates for early-stage
OA treatment, especially osteoporotic OA. These drugs
are potent in antagonizing bone resorption, which can
effectively decrease bone remodeling and prevent sub-
chondral bone loss and the deterioration of microarchi-
tecture and biomechanical properties [18, 19, 23]. Thus,
the protective effect of these drugs on articular cartilage
may be an indirect effect through protection of the sub-
chondral bone. Additionally, these drugs directly target
cartilage tissue, preventing cartilage damage and main-
taining healthy cartilage [26, 66]. In addition to the dir-
ect or indirect protective role of these drugs on articular
cartilage, subchondral bone, and the surrounding joint
tissues, including the synovium and muscle, the joint
tissues themselves interact with each other, thusmaintaining joint organ homeostasis as a whole and
finally delaying joint degeneration [56].
Moreover, the beneficial effect of estrogen-related
drugs on OA may be, at least in part, associated with
amelioration of the abnormal mechanical stress via or by
regulating ER. Mechanical stress has an important role
in the pathogenesis of OA [67], whereby abnormal
mechanical stress is reported to promote deterioration
of the subchondral bone and articular cartilage during
OA progression [68]. A recent study has reported that
estrogen reduces mechanical injury-related cell death
and proteoglycan degradation in an ER-mediated path-
way in mature articular cartilage. This suggests that es-
trogen agents ameliorate abnormal mechanical stress to
protect cartilage-related sports injuries or OA [27].
On the contrary, downregulation of ER expression is
evident during cartilage degeneration [69, 70], which
may be associated with abnormal mechanical stress [27].
More recently, lower serum estrogen has been shown to
downregulate ER expression, with estrogen therapy up-
regulating ER expression [70, 71], a finding that may re-
late to the beneficial effects of estrogen agents on OA.
In fact, these changes are similar to ER changes in disc
degeneration and its estrogen therapy [69, 72].
In summary, abnormal mechanical stress changes
the articular microenvironment to decrease expression
of ERs, which is associated with subsequent joint de-
generation. We therefore hypothesize that the upregu-
lated expression of ER by estrogen may correlate with
amelioration of abnormal mechanical stress, a hypoth-
esis that warrants further investigation.
Efficacy of estrogen-related drugs on joint tissues
Current observational studies suggest that estrogen may
be involved in the progression of OA and have potential
protective effects on joint tissues. However, some studies
suggest that the role of estrogen is controversial and
warrants further study. In contrast, preclinical and clin-
ical studies indicate that SERMs not only have consist-
ently positive effects on OA [33, 36, 38, 39, 53, 54], but
also significantly reduce estrogen treatment-related ad-
verse events. However, the positive estrogen-like effects
of SERMs on bone tissue are weaker than those of estro-
gen [44], and therefore need to be strengthened. A
number of reasons may account for this interesting
phenomenon. First, estrogen has an extensive effect
in vivo, regulating many metabolic pathways within vari-
ous tissues [73, 74]. However, the interaction of these
metabolic pathways may weaken the effect of estrogen
on articular tissues in vivo. Conversely, SERMs exhibit
tissue-specific ER antagonist or agonist activity, with se-
lective effects on specific tissues [11–13]. Consequently,
the impact of other metabolic pathways on the effect of
SERMs in articular tissues is weaker than that of
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like effects in vivo [50]. New estrogen-like drugs are
continuously reported. For example, tissue-selective
estrogen complexes (TSECs) are a combination of an es-
trogen and one SERM, and demonstrate many features
of ideal SERMs [14]. Theoretically, estrogen could
reinforce the positive role of SERMs on bone tissue,
making the effects of TESCs on bone tissue more effect-
ive than SERMs, which has been verified in a clinical
trial [75]. Conversely, the many adverse reactions of es-
trogen could be antagonized by SERMs. We speculate
that the effects of TESCs on joint tissues may be greater
than those of SERMs, with a generally desirable safety
and tolerability profile. In short, TESCs may become
candidates for OA drugs in the future.
Safety and tolerability of estrogen-related drugs
Research has revealed that SERMs are suited for the
treatment of OA with relatively favorable safety and tol-
erability profiles.
Long-term estrogen therapy stimulates breast and
endometrial hyperplasia with significantly increased risk
of breast and endometrial cancer [73]. Moreover, this
drug increases the risk of cardiovascular events and
stroke, especially thromboembolic diseases [74]. These
adverse effects severely limit the clinical application of
estrogen.
SERMs selectively act on ERs in target tissues and the
adverse events of SERMs are significantly reduced com-
pared with estrogen [11]. Almost all SERMs have anti-
estrogenic action in the breast and do not increase the
risk of breast cancer. Moreover, some SERMs such as
tamoxifen, toremifene, and raloxifene can be used for
the treatment or prevention of estrogen-sensitive breast
cancer [44]. SERMs have relatively varied effects on the
uterus. Furthermore, very few SERMs, such as tamoxi-
fen, stimulate endometrial proliferation with the in-
creased risk of endometrial cancer. In fact, the majority
of SERMs have neutral or anti-estrogenic effects on the
endometrium and do not increase the risk of endomet-
rial cancer [13]. In addition, most SERMs do not in-
crease the risk of cardiovascular events [11]. Although
some SERMs are reported to slightly increase the inci-
dence of hot flashes or vulvar vaginal atrophy, the symp-
toms are mild and do not affect the clinical application
of SERMs. Currently, the primary limit of clinical appli-
cation of most SERMs is the increased risk of venous
thrombosis embolism [44].
Conclusion
At present, the roles of estrogen in joint tissues or OA
are controversial. However, SERMs have consistently
protective effects on joint tissues or in OA with rela-
tively favorable safety and tolerability profiles. SERMsand estrogen may represent therapeutic options to treat
joint diseases in the future. In particular, SERMs and estro-
gen may be beneficial for postmenopausal women with
osteoporotic OA or early-stage OA [2, 3, 5]. Although,
there is a wide range of SERMs, their chemical structure
and biological function are quite complex. Therefore, it is
difficult to identify the optimal types of SERMs to treat OA.
Further research is needed to identify the most suitable
types of SERMs to treat OA and to clearly identify their
action mechanisms on joint tissues. A new group of
estrogen-related drugs, TSECs are reported to have a bene-
ficial effect on bone tissue [75, 76]. Furthermore, TSECs
may have the potential to protect other joint tissues,
suggesting they may become favorable therapeutic alterna-
tives for treatment of OA. These findings warrant further
clarification in future preclinical and clinical studies.
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